Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Resistance in Breast Cancer
share announcement

Resistance in Breast Cancer

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: closed (15 December 2022) | Viewed by 11698

Special Issue Editors

Dr. Sonia Pernas

E-Mail Website
Guest Editor
1. Department of Medical Oncology, Catalan Institute of Oncology-Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain
2. Breast Cancer Group, Institut d'Investigacio Biomedica de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain
Interests: HER2; breast cancer; gene expression
Dr. Romualdo Barroso

E-Mail Website
Guest Editor
Oncology Center, Hospital Sírio-Libanês Brasília, Brasília, Brazil
Interests: triple-negative breast cancer; immunotherapy

Special Issue Information

Dear Colleagues,

Advances in the understanding of tumor biology have led to the development of novel targeted therapies, which have markedly improved the outcomes of patients with breast cancer. Despite this progress, most women with metastatic disease do not respond to subsequent therapies, due to de novo or acquired resistance, and 20–30% of patients with early breast cancer relapse. 

Moreover, breast cancer is, both clinically and biologically, a heterogenous disease, and not all patients experience the same benefit from the current systemic therapies. Early identification of biomarkers of response/resistance would help us to individualize treatment and spare patients from potentially ineffective and/or toxic therapies.  

It is our pleasure to invite you to this Special Issue, entitled Resistance to Breast Cancer, which aims to summarize well-known mechanisms of resistance to the various therapies currently available, but also to identify and validate novel and clinically significant biomarkers for the early prediction of response/resistance to therapy and the prognosis of breast cancer.

In this Special Issue, original research articles and cutting-edge reviews are welcome. Research areas may include (but are not limited to) the following: 
•    Biomarkers of endocrine resistance;
•    CDK 4/6 inhibitor resistance;
•    Breast cancer heterogeneity;  
•    Mechanisms of resistance to anti-Her2 therapies;
•    Mechanisms of resistance to ADCs; 
•    Mechanisms of immune evasion in triple-negative breast cancer;
•    Biomarkers of response and resistance to immune checkpoint inhibitors in breast cancer;
•    Mechanisms of resistance to PARP inhibitors.

We look forward to receiving your contributions!

Dr. Sonia Pernas
Dr. Romualdo Barroso
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biomarkers
  • endocrine resistance
  • CDK 4/6 inhibitors resistance
  • breast cancer heterogeneity
  • mechanisms of resistance to anti-HER2 therapies
  • immune checkpoint inhibitors

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

12 pages, 1341 KiB  
Review
Mechanisms of Resistance to Antibody–Drug Conjugates
by Rachel Occhiogrosso Abelman, Bogang Wu, Laura M. Spring, Leif W. Ellisen and Aditya Bardia
Cancers 2023, 15(4), 1278; https://doi.org/10.3390/cancers15041278 - 17 Feb 2023
Cited by 11 | Viewed by 4461
Abstract
Antibody–drug conjugates (ADCs), with antibodies targeted against specific antigens linked to cytotoxic payloads, offer the opportunity for a more specific delivery of chemotherapy and other bioactive payloads to minimize side effects. First approved in the setting of HER2+ breast cancer, more recent ADCs [...] Read more.
Antibody–drug conjugates (ADCs), with antibodies targeted against specific antigens linked to cytotoxic payloads, offer the opportunity for a more specific delivery of chemotherapy and other bioactive payloads to minimize side effects. First approved in the setting of HER2+ breast cancer, more recent ADCs have been developed for triple-negative breast cancer (TNBC) and, most recently, hormone receptor-positive (HR+) breast cancer. While antibody–drug conjugates have compared favorably against traditional chemotherapy in some settings, patients eventually progress on these therapies and require a change in treatment. Mechanisms to explain the resistance to ADCs are highly sought after, in hopes of developing next-line treatment options and expanding the therapeutic windows of existing therapies. These resistance mechanisms are categorized as follows: change in antigen expression, change in ADC processing and resistance, and efflux of the ADC payload. This paper reviews the recently published literature on these mechanisms as well as potential options to overcome these barriers. Full article
(This article belongs to the Special Issue Resistance in Breast Cancer)
►▼ Show Figures

Figure 1

18 pages, 1563 KiB  
Review
Overcoming Resistance to HER2-Directed Therapies in Breast Cancer
by Ilana Schlam, Paolo Tarantino and Sara M. Tolaney
Cancers 2022, 14(16), 3996; https://doi.org/10.3390/cancers14163996 - 18 Aug 2022
Cited by 22 | Viewed by 6753
Abstract
Human epidermal growth factor receptor 2 (HER2)-positive breast cancer accounts for around 15% of all breast cancers and was historically associated with a worse prognosis compared with other breast cancer subtypes. With the development of HER2-directed therapies, the outcomes of patients with HER2-positive [...] Read more.
Human epidermal growth factor receptor 2 (HER2)-positive breast cancer accounts for around 15% of all breast cancers and was historically associated with a worse prognosis compared with other breast cancer subtypes. With the development of HER2-directed therapies, the outcomes of patients with HER2-positive disease have improved dramatically; however, many patients present with de novo or acquired resistance to these therapies, which leads to early recurrences or progression of advanced disease. In this narrative review, we discuss the mechanisms of resistance to different HER2-targeted therapies, including monoclonal antibodies, small tyrosine kinase inhibitors, and antibody-drug conjugates. We review mechanisms such as impaired binding to HER2, incomplete receptor inhibition, increased signaling from other receptors, cross-talk with estrogen receptors, and PIK3CA pathway activation. We also discuss the role of the tumor immune microenvironment and HER2-heterogeneity, and the unique mechanisms of resistance to novel antibody-drug conjugates. A better understanding of these mechanisms and the potential strategies to overcome them will allow us to continue improving outcomes for patients with breast cancer. Full article
(This article belongs to the Special Issue Resistance in Breast Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop